2005
DOI: 10.1016/j.vaccine.2004.08.024
|View full text |Cite
|
Sign up to set email alerts
|

Vaccine related itching nodules and hypersensitivity to aluminium

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
2
1

Citation Types

1
8
0

Year Published

2005
2005
2018
2018

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 11 publications
(9 citation statements)
references
References 2 publications
1
8
0
Order By: Relevance
“… 15 which included 54 HD patients. In the general population, persistent pruritus and itching nodules have been reported after the use of Al-containing vaccines 19 21 . Bergfors et al .…”
Section: Discussionmentioning
confidence: 99%
“… 15 which included 54 HD patients. In the general population, persistent pruritus and itching nodules have been reported after the use of Al-containing vaccines 19 21 . Bergfors et al .…”
Section: Discussionmentioning
confidence: 99%
“…This is crucial since systemic distribution of allergen could lead to adverse side‐effects such as anaphylactic reactions. However, there are drawbacks associated with alum as an adjuvant (4, 6, 24, 25), and therefore the use of CBP as a means to improve the allergen formulation for ASIT was assessed.…”
Section: Discussionmentioning
confidence: 99%
“…Alum mainly acts via Th2 cellular immune response, which does not confer the best protection for viral infections such as HCV and HIV. Moreover, there are safety concerns with the use of alum as an adjuvant with reported cases of hypersensitivity and erythema ( 67 , 68 ). Well characterized agonists of innate immunity may serve as a better candidate of targeted vaccine adjuvants (Figure 2 ).…”
Section: Innate Immune Potentiator As Vaccine Adjuvantsmentioning
confidence: 99%